Floatz logo

Rovalpituzumab Tesirine

Medullary Thyroid Cancer

AbbVieantibody_drug_conjugatePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Medullary Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Selpercatinib
Eli Lilly and Company
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Tarlatamab
University of Arizona
Phase 2B
Oxodotreotide
M.D. Anderson Cancer Center
Phase 2CCC
Everolimus
National Cancer Institute (NCI)
Phase 1CCC

View all 36 →

Same molecule, other indications

Rovalpituzumab Tesirine is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
large cell neuroendocrine carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
prostate neuroendocrine neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →